P1/2, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
over 2 years ago
Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A)